Drug Profile
Research programme: CD40-Fas ligand fusion proteins - Apoxis
Latest Information Update: 23 Nov 2006
Price :
$50
*
At a glance
- Originator Apoxis
- Class
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Immunological disorders
Most Recent Events
- 28 Jun 2004 Preclinical trials in Immunological disorders in Switzerland (unspecified route)